KOD - Kodiak Sciences Inc.
| Previous Close | 6.98 |
| Open | 6.98 |
| Bid | 5.15 x 1800 |
| Ask | 8.13 x 2900 |
| Day's Range | 6.88 - 7.38 |
| 52 Week Range | 5.65 - 11.10 |
| Volume | 48,272 |
| Avg. Volume | 73,770 |
| Market Cap | 270.917M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.77 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.13 |
- PR Newswire•24 days ago
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
PALO ALTO, Calif. , March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
- PR Newswire•last month
Kodiak Sciences to Present at the Barclays Global Healthcare Conference
PALO ALTO, Calif. , March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble
The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble
- Zacks•2 months ago
Wall Street Takes Notice of These 4 Stocks - Should You?
With the market in a volatile state, Wall Street's top investors are sorting the most valuable stocks - should you follow?
- Motley Fool•2 months ago
The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow?
Kodiak Sciences, Microsoft, and General Motors are on Wall Street's radar right now. Should they be on yours as well?
- PR Newswire•2 months ago
Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
PALO ALTO, Calif. , Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
- Simply Wall St.•3 months ago
Have Insiders Been Buying Kodiak Sciences Inc. (NASDAQ:KOD) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
- PR Newswire•4 months ago
Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes
PALO ALTO, Calif., Dec. 24, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018. "We are excited to be included in these indexes among some of the most innovative public companies in the U.S., as we look to broaden our investor base following our successful IPO in October," said John Borgeson, Kodiak's Chief Financial Officer.
- PR Newswire•4 months ago
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
-- Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population. -- Twelve weeks after a single dose, median vision improvement from baseline of almost two lines of vision (9 eye chart letters) and median improvement in retinal edema of 121 microns were achieved across all three dose levels tested. -- No dose-limiting toxicities, drug-related adverse events, or intraocular inflammation were observed through each patients' last visit at 12 weeks.
- American City Business Journals•5 months ago
This year's Bay Area IPO batch remains up 44% despite market turbulence
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
- PR Newswire•5 months ago
Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights
PALO ALTO, Calif. , Nov. 16, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...
- American City Business Journals•6 months ago
Strong IPO pace continued in October but some cracks are showing
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
- American City Business Journals•6 months ago
Here are 10 Bay Area accelerators ranked as best in the U.S.
The Bay Area now has three startup accelerator programs ranted as the best in the nation, according to an annual ranking.
- PR Newswire•6 months ago
Kodiak Sciences Inc. Announces Closing of Initial Public Offering
PALO ALTO, Calif. , Oct. 10, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9 , 2018 of its initial public offering of 9,000,000 shares of common stock at ...
- PR Newswire•7 months ago
Kodiak Sciences Inc. Announces Pricing of Initial Public Offering
PALO ALTO, Calif. , Oct. 3, 2018 /PRNewswire/ -- Kodiak Sciences Inc. ("Kodiak") today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price ...
- Benzinga•7 months ago
IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Upwork Inc. (UPWK) will issue nearly 12.3 million shares between $10 and $12 Wednesday on the Nasdaq. Upwork’s online platform ...
